Rocket Pharmaceuticals, Inc.
RCKT
$3.39
-$0.15-4.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 105.91M | 108.26M | 101.96M | 95.16M | 86.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 264.18M | 270.22M | 273.21M | 270.79M | 266.80M |
| Operating Income | -264.18M | -270.22M | -273.21M | -270.79M | -266.80M |
| Income Before Tax | -257.30M | -258.03M | -258.75M | -258.08M | -253.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -257.30 | -258.03 | -258.75 | -258.08 | -253.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -257.30M | -258.03M | -258.75M | -258.08M | -253.26M |
| EBIT | -264.18M | -270.22M | -273.21M | -270.79M | -266.80M |
| EBITDA | -253.87M | -260.11M | -263.83M | -261.84M | -258.48M |
| EPS Basic | -2.51 | -2.63 | -2.73 | -2.75 | -2.79 |
| Normalized Basic EPS | -1.59 | -1.69 | -1.76 | -1.77 | -1.80 |
| EPS Diluted | -2.51 | -2.63 | -2.73 | -2.75 | -2.79 |
| Normalized Diluted EPS | -1.59 | -1.69 | -1.76 | -1.77 | -1.80 |
| Average Basic Shares Outstanding | 412.80M | 395.53M | 378.98M | 374.79M | 363.27M |
| Average Diluted Shares Outstanding | 412.80M | 395.53M | 378.98M | 374.79M | 363.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |